Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 503-506

  Czyzewski, Krzysztof ^a   Styczynski, Jan ^a   Krenska, Anna ^a   Debski, Robert ^a   Zajac Spychala, Olga ^b   Wachowiak, Jacek ^b   Wysocki, Mariusz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Barr virus; Central nervous system; Epstein ; Post transplant lymphoproliferative disorder; Rituximab

Indexed keywords

DIAZEPAM; RITUXIMAB; VIRUS DNA;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMNESIA; ANOREXIA; ARTICLE; BRAIN SCINTISCANNING; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL ARTICLE; CONSCIOUSNESS DISORDER; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FEMALE; FEVER; HEPATOMEGALY; HUMAN; MALE; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INJECTIONS, SPINAL; LYMPHOPROLIFERATIVE DISORDERS; MAGNETIC RESONANCE IMAGING; MALE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84873372745     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.718342     Document Type: Article

References (20)

1. Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009: 11: 383-392.
2. Suzuki M, Kosugi I, Terada T, et al. A case of Epstein-Barr virus associated post-transplant lymphoproliferative disorder with CNS involvement: pathological findings at both biopsy and autopsy. Neuropathology 2011;31: 440-445.
3. Aisa Y, Mori T, Nakazato T, et al. Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation. Transpl Infect Dis 2009;11: 438-441.
4. Kittan NA, Beier F, Kurz K, et al. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transpl Infect Dis 2011;13: 524-530.
5. Styczynski J, Gil L, Donnelly JP, et al. Use of rituximab for post-SCT EBV-PTLD: the final results of a retrospective EBMT study. Bone Marrow Transplant 2012;47(Suppl. 1): Abstract 291.
6. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009: 43: 757-770.
7. Martelius T, Lappalainen M, Palomaki M, et al. Clinical characteristics of patients with Epstein Barr virus in cerebrospinal fuid. BMCInfect Dis 2011;11: 281.
8. Bonney DK, Htwe EE, Turner A, et al. Sustained response to intrathecal rituximab in EBV associated post-transplant lymphoproliferative disease conf ned to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2012;58: 459-461.
9. Vaglio A, Manenti L, Mancini C, et al. EBV-associated leukoencephalopathy with late onset of central nervous system lymphoma in a kidney transplant recipient. Am J Transplant 2010: 10: 947-951.
10. Nozzoli C, Bartolozzi B, Guidi S, et al. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006: 47: 167-169.
11. Jahnke K, Doolittle ND, Muldoon LL, et al. Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus 2006: 21: E11.
12. van de Glind G, de Graaf S, Klein C, et al. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008: 50: 886-888.
13. Harjunpaa A, Wiklund T, Collan J, et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001: 42: 731-738.
14. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O, et al. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 2009;144: 794-795.
15. Schulz H, Pels H, Schmidt-Wolf I, et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibodyrituximab. Haematologica 2004;89: 753-754.
16. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25: 1350-1356.
17. Liu CY, Teng HW, Lirng JF, et al. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma 2008;49: 2018-2021.
18. Kordelas L, Trenschel R, Koldehof M, et al. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 2008: 31: 691-693.
19. Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an interna-tional primary central nervous system lymphoma collaborative group report. Cancer 2010;116: 863-870.
20. Stephan JL, Le Deist F, Blanche S, et al. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation 1992: 54: 246-249.